|1.||Hein, Misty J: 4 articles (04/2014 - 05/2010)|
|2.||Carreón, Tania: 4 articles (04/2014 - 05/2010)|
|3.||Hanley, Kevin W: 4 articles (04/2014 - 05/2010)|
|4.||Viet, Susan M: 4 articles (04/2014 - 05/2010)|
|5.||Ruder, Avima M: 4 articles (04/2014 - 05/2010)|
|6.||Drexler, Hans: 2 articles (05/2009 - 01/2006)|
|7.||Angerer, Jürgen: 2 articles (05/2009 - 01/2006)|
|8.||Markowitz, Steven B: 2 articles (09/2005 - 02/2004)|
|9.||Nakajima, Miki: 1 article (06/2013)|
|10.||Yokoi, Tsuyoshi: 1 article (06/2013)|
|2.||Urinary Bladder Neoplasms (Bladder Cancer)
03/01/2014 - "Despite other concurrent chemical exposures, we consider o-toluidine most likely responsible for the bladder cancer incidence elevation and recommend a re-examination of occupational exposure limits."
11/01/2012 - "Occupational exposure to o-toluidine is associated with an increased risk of bladder cancer but human disease rates could not be used to establish risk values due to inadequate exposure data and coexposures in the epidemiology cohorts. "
10/01/2008 - "In simultaneous analyses of the four exposure history variables, Poisson regression showed a significant positive trend for bladder cancer risk in relation to cumulative duration of employment in the ortho-toluidine department (P < 0.05) and non-significant positive trends in relation to cumulative duration of employment in the PBN department and to cumulative exposure to MBT. "
09/01/2005 - "Continued epidemic of bladder cancer in workers exposed to ortho-toluidine in a chemical factory. "
02/01/2004 - "The timing of onset of exposure to o-toluidine of numerous cases of bladder cancer after 1968, and especially 1975, suggests that potentially confounding occupational exposures other than o-toluidine were not responsible for the observed excess bladder cancer. "
10/01/2007 - "Prilocaine HCl is quickly hydrolyzed to o-toluidine, causing methemoglobinemia. "
11/01/2003 - "This study investigated in vivo and in vitro kinetics of o-toluidine-induced methemoglobinemia and the influence of ascorbic acid on resulting methemoglobin concentrations. "
11/01/2003 - "o-Toluidine is a metabolite of prilocaline and ascorbic acid is recommended for treatment of methemoglobinemia as an alternative to methylene blue. "
06/01/2013 - "Although the hydrolyzed metabolites of prilocaine (o-toluidine) and lidocaine (2,6-xylidine) have been suspected to induce methemoglobinemia, the metabolic enzymes that are involved remain uncharacterized. "
01/01/1995 - "EMLA (eutectic mixture of lidocaine and prilocaine) cream is currently not recommended for use in infants < 1 month of age because of the potential risk of methemoglobinemia as a result of the o-toluidine metabolite of prilocaine. "
03/01/1996 - "The apparently lower potency of o-toluidine hydrochloride relative to o-o-nitrotoluene in the induction of mesothelioma suggests that simple intestinal reduction of the nitro group may not be sufficient for carcinogenic activity in the mesothelium. "
03/01/1996 - "The incidence of mesothelioma was greater and the latency was less in rats administered o-nitrotoluene than in rats administered o-toluidine hydrochloride. "
03/01/1996 - "The results of these studies demonstrate the somewhat greater relative carcinogenic potential of o-nitrotoluene compared to o-toluidine hydrochloride after 13 or 26 weeks of administration based on the occurrence of mesothelioma and cholangiocarcinoma. "
03/01/1996 - "o-Nitrotoluene and o-toluidine hydrochloride caused mesothelial hyperplasia and mesothelioma in male rats after 13 or 26 weeks of dietary exposure. "
|1.||aniline (aniline hydrobromide)
|3.||4-Aminobenzoic Acid (4 Aminobenzoic Acid)
|6.||Transferrin (beta 2 Transferrin)
|8.||Ascorbic Acid (Vitamin C)